HDL and inflammation in atherosclerosis.

Curr Drug Targets Immune Endocr Metabol Disord

Cardiology, Cardiovascular Center, University Hospital, Zürich, Switzerland.

Published: March 2004

Atherosclerotic vascular disease is among the most frequent causes of death worldwide. Current therapeutic strategies concentrate mainly on lowering of low-density lipoprotein (LDL) cholesterol and an impressive reduction in the risk for cardiovascular morbidity and mortality has been achieved. Inflammatory mechanisms are more and more recognized to play an important role in vascular disease as inflammatory markers correlate with prognosis in acute and chronic coronary artery disease. HDL cholesterol exerts anti-inflammatory effects on the vasculature. Moreover, HDL is an antioxidant, inhibits thrombogenesis, and has pro-fibrinolytic properties. Last but not least, HDL mediates reverse cholesterol transport. These pleiotropic effects make HDL an ideal therapeutic target for novel therapeutic strategies specifically aiming at HDL elevation for the prevention and treatment of atherosclerotic vascular disease.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568008043340044DOI Listing

Publication Analysis

Top Keywords

vascular disease
12
atherosclerotic vascular
8
therapeutic strategies
8
hdl
6
hdl inflammation
4
inflammation atherosclerosis
4
atherosclerosis atherosclerotic
4
disease
4
disease frequent
4
frequent death
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!